These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2328805)

  • 21. Anticoagulant activity of galactosaminoglucuronoglycan: a pharmacological study.
    Matera M; Scalia S
    Drugs Exp Clin Res; 1991; 17(1):65-73. PubMed ID: 1833172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Interaction of quinidine, lidocaine, tricaine and pyromecaine with heparin].
    Ushkalova EA; Petrov AD; Shcheglova NV
    Farmakol Toksikol; 1989; 52(4):43-5. PubMed ID: 2806526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro evidence of gender-related heparin resistance.
    Monte S; Lyons G
    Int J Obstet Anesth; 2004 Apr; 13(2):91-4. PubMed ID: 15321411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The anticoagulant capacity of plasmatic unfractionated heparin decreases at 23 degrees C.
    Stief TW
    Blood Coagul Fibrinolysis; 2007 Mar; 18(2):209-12. PubMed ID: 17287642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
    Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
    Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long duration of anticoagulant activity and protective effects of acharan sulfate in vivo.
    Li DW; Lee IS; Sim JS; Toida T; Linhardt RJ; Kim YS
    Thromb Res; 2004; 113(1):67-73. PubMed ID: 15081567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fucosylated chondroitin sulfate as a new oral antithrombotic agent.
    Fonseca RJ; Mourão PA
    Thromb Haemost; 2006 Dec; 96(6):822-9. PubMed ID: 17139379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Comparative study of the effect of the antimalarials dabequin and chloroquine on retinal ultrastructure in the rat].
    Ivanina TA; Lebedeva MN
    Vestn Oftalmol; 1982; (3):53-6. PubMed ID: 7112855
    [No Abstract]   [Full Text] [Related]  

  • 29. [Antithrombin III activity in relation to multiple administration of various doses of heparin to normal animals].
    Kudriashov BA; Pastorova VE; Liapina LA
    Vopr Med Khim; 1985; 31(3):37-41. PubMed ID: 4024529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-hemostatic action of heparin: relationship between topical and intravenous application.
    Magalhàes JR; Unglert CV; Damiani H; Nogueira Filho J
    Acta Physiol Lat Am; 1971; 21(3):209-15. PubMed ID: 5158678
    [No Abstract]   [Full Text] [Related]  

  • 31. [Site of action of anticoagulant drugs].
    Capel P
    Rev Med Brux; 1985 Mar; 6(3):131-3. PubMed ID: 3992078
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
    Pindur G; Heiden M; Köhler M
    Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of group F prostaglandins on the hemostatic properties the gastrointestinal tract tissues].
    Glants RM; Tkach EA
    Probl Gematol Pereliv Krovi; 1979 May; 24(5):38-42. PubMed ID: 450897
    [No Abstract]   [Full Text] [Related]  

  • 34. Inhibition rather than enhancement of hemostatic system activation during initiation of oral anticoagulant treatment.
    Kyrle PA; Brockmeier J; Weltermann A; Eichinger S; Speiser W; Lechner K; Eichler HG
    Thromb Haemost; 1997 Apr; 77(4):685-9. PubMed ID: 9134643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Interaction of heparin and thrombocytes (a review of the Soviet and foreign literature)].
    Traskunova NV; Rokhmistrova VD
    Vestn Khir Im I I Grek; 1980 Apr; 124(4):142-6. PubMed ID: 6992400
    [No Abstract]   [Full Text] [Related]  

  • 36. [Principles of the treatment of hypercoagulabilities with a rational anticoagulant therapy].
    Raby C
    Presse Med (1893); 1969 Jan; 77(1):17-9. PubMed ID: 5785756
    [No Abstract]   [Full Text] [Related]  

  • 37. [Action of doxorubicin and a doxorubicin-heparin complex on the growth and metastasis of experimental tumors and the hemostatic system indices].
    Kalishevskaia TM; Bashkov GV; Repina NIu; Shpilevaia MV; Modina LS
    Eksp Onkol; 1988; 10(4):59-62. PubMed ID: 3181077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The significance of TFPI in clotting assays--comparison and combination with other anticoagulants.
    Nordfang O; Kristensen HI; Valentin S; Ostergaard P; Wadt J
    Thromb Haemost; 1993 Sep; 70(3):448-53. PubMed ID: 8259547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hemostatic system in obstructive lung diseases and its changes in the course of treatment with low heparin doses].
    Il'chenko VA; Levantovskaia OM; Tsar'kova LN; Rozanova LA; Paleev NR
    Ter Arkh; 1985; 57(9):109-12. PubMed ID: 4082034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Changes in the adhesiveness of thrombocytes under the effect of anticoagulants].
    Merkulov MF; Lakin KM; Fel'dbaum VA; Efimov VS
    Farmakol Toksikol; 1968; 31(6):706-9. PubMed ID: 5713582
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.